CONTENTS VOL. 18, 2000

Volume 18, No. 1

Preclinical Study

In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood – O. Combes, J. Barré, J.-C. Duché, L. Vernillet, Y. Archimbaud, M.P. Marietta, J.-P. Tillement, S. Urien 1–5

Review Articles

Development of target-based antineoplastic agents – W.M. Stadler, M.J. Ratain 7–16

Advanced non-small cell lung carcinoma: The emerging role of docetaxel – C.J. Langer 17–28

Gemcitabine in non-small cell lung cancer (NSCLC) – C. Manegold, P. Zatloukal, K. Krejcy, J. Blatter 29–42

Current approaches and future strategies for pancreatic carcinoma – R.A. Wolff, P. Chiao, R. Lenzi, P.W.T. Pisters, J.E. Lee, N.A. JanJan, C.H. Crane, D.B. Evans, J.L. Abbruzzese 43–56

Promising approaches in acute leukema – J. Cortes, H.M. Kantarjian 57–82

Phase I Study

A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer – G. Schwartsmann, H. Schunemann, C.N.F. Gorini, A.F. Ferreira Filho, C. Garbino, G. Sabini, I. Muse, L. DiLeone, D.R. Mans 83–91

Volume 18, No. 2

Preclinical studies

UCN-01 enhances the *in vitro* toxicity of clinical agents in human tumor cell lines – A. Monks, E.D. Harris, A. Vaigro-Wolff, C.D. Hose, J.W. Connelly, E.A. Sausville 95–107

Proteasome inhibition: a new strategy in cancer treatment – J. Adams, V.J. Palombella, P.J. Elliott 109–121

DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs – E. Raymond, J.-C. Soria, E. Izbicka, F. Boussin, L. Hurley, D.D. Von Hoff 123–137

Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines – M. Taron, C. Plasencia, A. Abad, C. Martin, M. Guillot 139–147

Cdc25 as a potential target of anticancer agents – J.W. Eckstein 149–156

Clinical review

Chemotherapy in non-small cell lung cancer – C.J. Sweeney, A.B. Sandler 157–186

Phase II studies

CI-980 in advanced melanoma and hormone refractory prostate cancer – C.W. Ryan, K.L. Shulman, J.M. Richards, J.W. Kugler, J.A. Sosman, R.H. Ansari, E.E. Vokes, N.J. Vogelzang 187–191

A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma – E.J. Small, R. Figlin, D. Petrylak, D.J. Vaughn, O. Sartor, I. Horak, R. Pincus, A. Kremer, C. Bowden 193–197

A phase II trial of topotecan in esophageal carcinoma: A Southwest Oncology Group study (SWOG 9339) – J.S. Macdonald, J.L. Jacobson, S.J Ketchel, G. Weiss, S. Taylor, G. Mills, J.P. Kuebler, S. Rivkin, M. Conrad 199–202

Volume 18, No. 3

Preclinical reviews

Development of multidrug-resistance convertors: sense or nonsense? – L. van Zuylen, K. Nooter, A. Sparreboom, J. Verweij 205–220

Studies on the cytotoxic, biochemical and anti-carcinogenic potentials of ninhydrin on Ehrlich ascites carcinoma cell-bearing Swiss albino mice – S. Qureshi, O.A. Al-Shabanah, A.M. Al-Bekairi, M.M. Al-Harbi, N.M. Al-Gharably, M. Raza 221–230

Clinical review

The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery – H.A. Bardelmeijer, O. van Tellingen, J.H.M. Schellens, J.H. Beijnen 231–241

Phase II studies

Phase II study of intravenous Doxil® in malignant pleural mesothelioma – Y. Oh, R. Perez-Soler, F.V. Fossella, B.S. Glisson, J. Kurie, G.L. Walsh, M. Truong, D.M. Shin 243–245

Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma – P.M. Dodd, J.A. McCaffrey, M. Mazumdar, E. Icasiano, G. Higgins, H. Herr, D.F. Bajorin 247–251

Phase II trial of liposomal doxorubicin (Doxil®) in advanced soft tissue sarcomas – T. Chidiac, G.T. Budd, R. Pelley, K. Sandstrom, D. McLain, P. Elson, R. Crownover, K. Marks, G. Muschler, M. Joyce, R. Zehr, R. Bukowski 253–259

Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer – T. Lad, F. Rosen, D. Sciortino, B. Brockstein, J.P. Keubler, R. Arietta, E. Vokes 261–263

Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors – J. Vuky, J. McCaffrey, M. Ginsberg, T. Mariani, D.F. Bajorin, G.J. Bosl, R.J. Motzer 265–267

A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413) – J.S. Macdonald, J.L. Jacobson, M. Modiano, D.F. Moore, D.R. Gandara, L.E. Schroder, R.A. Chapman 269–273

A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas – P.A. Burch, A.M. Bernath, T.L. Cascino, B.W. Scheithauer, P. Novotny, S. Nair, J.C. Buckner, D.M. Pfeifle, J.W. Kugler, L.K. Tschetter 275–280

A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors – J.T. Hartmann, L.M. Fels, S. Knop, H. Stolte, L. Kanz, C. Bokemeyer 281–289

Volume 18, No. 4

Introduction – R. Pazdur 297–298

5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development – J.L. Grem 299–313

Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan – T. Shirasaka, S. Yamamitsu, A. Tsuji, T. Taguchi 315–329

The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovonin (ORZEL) and S-1: a review of their clinical development and therapeutic potential – P.M. Hoff 331–342

Capecitabine: preclinical pharmacology studies – H. Ishitsuka 343–354

Capecitabine – D.R. Budman 355–363

Preclinical development of eniluracil: Enhancing the therapeutic index and dosiing convenience of 5-fluorouracil – M.T. Paff, D.P. Baccanari, S.T. Davis, S. Cao, R.L. Tansik, Y.M. Rustum, T. Spector 365-371

Pharmacology of fluorinated pyrimidines: Eniluracil – S.D. Baker 373–381

Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors – J. Levin, J. Hohneker 383–390

Contents Volume 18, 2000 391–393

Author Index 395–396

Instructions for authors 397–401